OAC
ARTV

OMERS Administration Corp’s Artiva Biotherapeutics ARTV Stock Holding History

OMERS Administration Corp’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.4K Sell
11,400
-9,700
-46% -$48K ﹤0.01% 1042
2025
Q4 		$90.5K Buy
+21,100
New +$79.7K ﹤0.01% 977

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

OMERS Administration Corp's ARTV Position: Q1 2026 in Review

OMERS Administration Corp reduced its Artiva Biotherapeutics (ARTV) stake by 46% in Q1 2026, selling an estimated $48K and leaving 11,400 shares worth $73.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1042.

OMERS Administration Corp first reported a position in ARTV in Q4 2025 and has held it in 2 quarters since. The position peaked at $90.5K in Q4 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • OMERS Administration Corp held 11,400 shares of Artiva Biotherapeutics worth $73.4K as of Q1 2026.
  • OMERS Administration Corp sold 9,700 Artiva Biotherapeutics shares in Q1 2026, an estimated $48K.
  • Artiva Biotherapeutics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #1042 holding.
  • OMERS Administration Corp first reported a position in Artiva Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • OMERS Administration Corp's Artiva Biotherapeutics position peaked at $90.5K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.